ValiRx Plc’s VAL201 compound gets the US Patent

  • Nov 28, 2019 GMT
  • Team Kalkine
  • ValiRx Plc (LON: VAL) has reported that its lead therapeutic compound, VAL201 has been granted the US Patent No. 10,400,008 and title: "Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer from the US Patent and Trademark Office.
  • The VAL201 compound of the company selectively thwarts tumour growth by explicitly preventing the spread of tumour cells.
  • The grant provides patent protection for a method of thwarting the deterioration of indications of metastatic cancer, decreasing the advancement of a metastatic cancer, or curing metastatic cancer (including prostate cancer) using the VAL201 peptide.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK